Can I Take Vitamin B12 with Avodart (Dutasteride)?

The Short Answer: No Interaction Between Dutasteride and Vitamin B12

Dutasteride and vitamin B12 occupy entirely separate biological lanes. Dutasteride works by blocking 5-alpha reductase types 1 and 2, which converts testosterone to the more potent dihydrotestosterone (DHT). Vitamin B12 (cobalamin) functions as a cofactor in one-carbon metabolism, DNA synthesis, and myelin maintenance. There is no shared receptor, no shared enzyme family, and no shared transporter that would cause these two agents to interfere with each other.

Why Pharmacokinetic Conflict Is Essentially Zero

Dutasteride is eliminated almost entirely by hepatic metabolism. The cytochrome P450 enzymes CYP3A4 and CYP3A5 handle the bulk of its breakdown, producing inactive hydroxylated metabolites [1]. Vitamin B12 bypasses hepatic CYP metabolism altogether. In the gut, dietary or supplemental B12 binds intrinsic factor (a glycoprotein secreted by gastric parietal cells), and the resulting complex is absorbed across ileal enterocytes via the cubam receptor system [2]. Once inside cells, B12 travels as transcobalamin II. None of these steps touch CYP3A4 or CYP3A5.

The FDA-approved labeling for dutasteride (Avodart, GlaxoSmithKline) lists potent CYP3A4 inhibitors such as ritonavir and ketoconazole as agents that can raise dutasteride plasma levels. Vitamin B12 is not a CYP inhibitor or inducer at any clinically relevant dose [3].

Pharmacodynamic Overlap: Also Absent

On the pharmacodynamic side, dutasteride's target is 5-alpha reductase in the prostate, skin, and liver. Vitamin B12's targets are methionine synthase and methylmalonyl-CoA mutase, two enzymes in the methylation and propionate pathways. These pathways do not converge in a way that would amplify or blunt either agent's effect [4].

Understanding Dutasteride: How It Works and Who Takes It

Dutasteride (brand name Avodart, 0.5 mg oral capsule) is a dual inhibitor of 5-alpha reductase types 1 and 2. This dual inhibition suppresses serum DHT by approximately 90-95% within two weeks of starting therapy, compared with the roughly 70% suppression achieved by finasteride, which targets only type 2 [5].

Approved and Off-Label Uses

The FDA approved dutasteride 0.5 mg/day for the treatment of symptomatic benign prostatic hyperplasia (BPH) in 2001. The COMBAT trial (N=4,844, 4 years) showed that the combination of dutasteride plus tamsulosin reduced the risk of acute urinary retention by 68% compared with tamsulosin alone [6].

Off-label, clinicians prescribe dutasteride at 0.5 mg/day for androgenetic alopecia (male and female pattern hair loss). A 2021 randomized controlled trial (N=153) published in the Journal of the American Academy of Dermatology found dutasteride 0.5 mg/day produced greater hair count increases than finasteride 1 mg/day at 24 weeks (P<0.001) [7].

Who Is Most Likely to Also Need B12?

Men taking dutasteride for BPH frequently share demographic features that raise B12 deficiency risk:

• Age 50 and older, where gastric atrophy reduces intrinsic factor secretion
• Type 2 diabetes managed with metformin (see section below)
• Proton pump inhibitor (PPI) use for gastroesophageal reflux, which reduces gastric acid needed to release food-bound B12
• Vegan or vegetarian diets

This overlap means a B12 conversation is clinically relevant for a substantial portion of men prescribed Avodart, even though the drug itself is not the cause of depletion.

Vitamin B12: What It Does and Why Deficiency Matters

Vitamin B12 is a water-soluble vitamin that the human body cannot synthesize. Adults need roughly 2.4 mcg per day from dietary sources (meat, fish, dairy, eggs) or supplements [8]. Deficiency is common: data from the National Health and Nutrition Examination Survey suggest approximately 6% of U.S. Adults under 60 and nearly 20% of those over 60 are B12 deficient by standard serum cutoffs [9].

Neurological Consequences of Deficiency

B12 deficiency is not benign. Sustained low levels demyelinate peripheral nerves and the posterior and lateral columns of the spinal cord. Clinical presentations include subacute combined degeneration, peripheral neuropathy with numbness and tingling in a stocking-glove distribution, cognitive decline, and megaloblastic anemia. The National Institutes of Health Office of Dietary Supplements notes that neurological damage from B12 deficiency can become irreversible if not treated within months [8].

This matters in the context of Avodart because men experiencing peripheral neuropathy symptoms while taking the drug may incorrectly attribute the symptom to dutasteride rather than investigating B12 status.

Forms of B12 Supplements

Supplement labels list several forms:

• Cyanocobalamin: synthetic, stable, widely studied, converted to active forms in the body
• Methylcobalamin: already in active form, preferred by some clinicians for neurological indications
• Adenosylcobalamin: mitochondrial form, less commonly sold as a standalone
• Hydroxocobalamin: used in injectable formulations for deficiency treatment

For oral supplementation in deficiency, doses of 1,000-2,000 mcg/day of cyanocobalamin or methylcobalamin are supported by clinical guidelines. High oral doses partially bypass the intrinsic factor system via passive diffusion, making them effective even in cases of impaired absorption [8].

The Metformin Connection: A Real Risk for Some Dutasteride Users

This is where clinical nuance matters most. Dutasteride itself does not deplete B12. Metformin, however, reliably does.

Men with BPH frequently have metabolic syndrome. Metformin is first-line therapy for type 2 diabetes and is also prescribed off-label for insulin resistance, PCOS, and longevity protocols. The co-prescription of dutasteride and metformin in middle-aged to older men is common in endocrinology and urology practices.

How Metformin Depletes B12

Metformin reduces B12 absorption by competing with the calcium-dependent ileal membrane receptor that facilitates cubam-mediated uptake of the intrinsic factor-B12 complex. A landmark 10-year randomized controlled trial from the Diabetes Prevention Program Outcomes Study (DPPOS, N=2,155) found that metformin use was associated with a 19% higher rate of B12 deficiency compared with placebo, and that deficiency was more pronounced with longer duration of use [10].

A separate analysis published in Diabetes Care found that 30% of long-term metformin users had low or borderline B12 levels [11]. The American Diabetes Association's Standards of Medical Care (2024 edition) states: "Long-term use of metformin is associated with biochemical B12 deficiency. Periodic measurement of B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy" [12].

A Practical Decision Framework for Men on Both Dutasteride and Metformin

Use this stepwise approach when a patient is on dutasteride and metformin together:

1. Baseline serum B12 at prescribing. Draw serum cobalamin before starting metformin or at the first combined visit. A level <300 pg/mL in a patient with neurological symptoms warrants treatment regardless of the strict deficiency cutoff.
2. Annual re-check after year one. The DPPOS data showed deficiency rates increased over time, so a single normal level does not confer permanent reassurance.
3. Supplement proactively if the diet is low in animal products. Oral 1,000 mcg/day cyanocobalamin or methylcobalamin is inexpensive, safe at this dose, and corrects metformin-induced malabsorption via passive diffusion.
4. Distinguish neuropathy sources carefully. Peripheral neuropathy in a diabetic man on dutasteride plus metformin could reflect diabetic neuropathy, B12 deficiency neuropathy, or both. Check serum B12 and methylmalonic acid (MMA) before attributing symptoms to any one cause.
5. Refer to neurology if MMA is elevated despite B12 supplementation, since other causes of methylmalonic acidemia need to be excluded.

CYP3A4 Interactions: Supplements That Actually Matter With Dutasteride

Since no interaction exists between dutasteride and B12, a brief review of supplements that do carry dutasteride interaction signals gives useful clinical context.

St. John's Wort: CYP3A4 Inducer

St. John's Wort (hyperforin) is a well-documented CYP3A4 inducer. Consistent use could theoretically accelerate dutasteride metabolism, reducing plasma concentrations and potentially diminishing BPH or hair loss benefit. The FDA label for dutasteride advises caution with strong CYP3A4 inducers [3].

Grapefruit and Grapefruit Juice: CYP3A4 Inhibitor

Furanocoumarins in grapefruit irreversibly inhibit intestinal CYP3A4. This could raise dutasteride plasma levels, though clinical case reports specifically with dutasteride are absent from the literature. The interaction is mechanistically plausible given dutasteride's CYP3A4 dependence.

Saw Palmetto: Pharmacodynamic Overlap

Saw palmetto (Serenoa repens) has weak 5-alpha reductase inhibiting activity in vitro. Combining it with dutasteride adds a pharmacodynamic layer, though controlled trial data on this combination are limited. Clinicians should note the overlap when patients report taking saw palmetto alongside Avodart.

Monitoring Parameters for Men Taking Dutasteride Long-Term

Dutasteride requires a specific monitoring framework beyond the B12 question.

PSA Interpretation

Dutasteride suppresses prostate-specific antigen (PSA) by approximately 50% after 6 months of therapy. The FDA label for Avodart states that any confirmed increase in PSA while on dutasteride should be evaluated even if the value remains within the normal range, since the expected suppression means a "normal" value may represent a meaningful rise from suppressed baseline [3]. Urologists typically double the measured PSA to estimate the "nadir-corrected" value for comparison with pre-treatment levels.

Sexual Side Effects

The REDUCE trial (N=6,729, 4 years) reported ejaculatory disorders in 1.4% of dutasteride-treated men versus 0.5% placebo, decreased libido in 3.3% versus 1.6% placebo, and impotence in 4.7% versus 2.1% placebo at the 1-year mark, with rates declining over time [13]. These are pharmacodynamic effects of DHT suppression, unrelated to B12 status.

Breast Tissue Changes

Gynecomastia and breast tenderness were reported in 1.1% of men in dutasteride trials. This reflects the shift in androgen-to-estrogen ratio when DHT is suppressed. B12 supplementation does not influence this mechanism.

Practical Guidance: Taking B12 Alongside Avodart

Given the absence of interaction, there are no special timing requirements. A man taking dutasteride 0.5 mg once daily can take his B12 supplement at any time. Below is a brief, pragmatic checklist:

• No dose separation needed. B12 and dutasteride do not compete for absorption, metabolism, or receptor binding.
• Form preference. Methylcobalamin 1,000 mcg/day is a reasonable starting point for men with neurological concerns. Cyanocobalamin 1,000-2,000 mcg/day is supported by the most evidence for correcting deficiency.
• Food does not affect B12 absorption from supplements at high oral doses, since passive diffusion dominates at these concentrations.
• Avoid mega-doses without reason. There is no established clinical benefit to exceeding 5,000 mcg/day for most indications, and very high doses are generally unnecessary.
• Tell your prescriber about all supplements. Even though B12 is safe with dutasteride, your prescriber needs a complete picture to catch interactions involving other agents in your regimen.

What the Evidence Actually Shows: A Summary of the Key Data Points

Pulling the primary evidence together in one place:

1. The Avodart FDA-approved prescribing information lists CYP3A4 inhibitors/inducers as clinically relevant drug interactions. Vitamin B12 is not in this category [3].

2. The NIH Office of Dietary Supplements Fact Sheet for B12 confirms absorption via the cubam receptor and notes that "the body absorbs less than 10 mcg of crystalline B12 from a 500 mcg supplement." This passive-diffusion mechanism is entirely independent of hepatic CYP metabolism [8].

3. The DPPOS (N=2,155, 10 years) found a statistically significant increase in B12 deficiency with metformin: 19% higher deficiency rates vs. Placebo, with a dose-dependent pattern [10].

4. A 2021 meta-analysis in the Annals of Internal Medicine (N=21 trials) confirmed that oral B12 supplementation at 1,000-2,000 mcg/day is as effective as intramuscular injection for correcting most causes of deficiency, including malabsorption-related causes [14].

5. The 2024 ADA Standards of Medical Care explicitly recommend periodic B12 monitoring in long-term metformin users [12].